Trials / Unknown
UnknownNCT02717741
A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor
A Phase I Study to Determine the Safety and Pharmacokinetic Study of Tafetinib in Patients With Advanced Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Tafetinib is an oral multitargeted tyrosine kinase inhibitor that inhibits Vascular Endothelial Growth Factor Receptor (VEGFR). This phase I trial was conducted to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of tafetinib in Chinese patients with advance solid tumor. The study are conducting in Cancer Hospital Chinese Academy of Medical Sciences.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tafetinib |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2016-03-24
- Last updated
- 2016-03-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02717741. Inclusion in this directory is not an endorsement.